![]() |
Lung Cancer |
Free Subscription
1 AJR Am J Roentgenol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Lung Cancer is free of charge.
Risk-Based Selection for Invasive Mediastinal Staging in Nonsmall Cell Lung
Cancer: Role of Preoperative Imaging.
AJR Am J Roentgenol. 2025 Mar 5. doi: 10.2214/AJR.25.32890.
PubMed
Medicaid Expansion is Associated with Differences in Local Therapy for Non-small
Cell Lung Cancer.
Ann Surg Oncol. 2025 Mar 5. doi: 10.1245/s10434-025-17082.
PubMed
Abstract available
The Landmark Series: Advances in Preoperative Mediastinal Lymph Node Staging for
Non-small Cell Lung Cancer (NSCLC).
Ann Surg Oncol. 2025 Mar 1. doi: 10.1245/s10434-025-17008.
PubMed
Abstract available
Significance of Tumor Microvasculature in the Tumor Microenvironment in
Adenocarcinoma with EGFR Common Mutations.
Ann Surg Oncol. 2025;32:3031-3039.
PubMed
Abstract available
Prognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM
Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.
Ann Surg Oncol. 2025;32:2912-2922.
PubMed
Abstract available
Tumor Spread Through Air Spaces Predicts Survival in Resected Pulmonary
Lymphoepithelial Carcinoma.
Ann Surg Oncol. 2025;32:2675-2686.
PubMed
Abstract available
Evaluation of uncertain resection for localized non-small cell lung cancer: the
crucial prognosis of suboptimal lymph node assessment.
Ann Thorac Surg. 2025 Feb 27:S0003-4975(25)00170.
PubMed
Abstract available
Peripheral CD4(+) T Cells Predict T Cell Immunity in Lung Tissues of Non-small
Cell Lung Cancer Patients.
Anticancer Res. 2025;45:909-920.
PubMed
Abstract available
Impact of Postoperative Therapy on Survival Outcomes in Non-small Cell Lung
Cancer Patients With Microscopic Residual Disease.
Anticancer Res. 2025;45:1193-1204.
PubMed
Abstract available
Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in
Non-small Cell Lung Cancer.
Anticancer Res. 2025;45:1105-1115.
PubMed
Abstract available
Survival impact and risk factors of skeletal muscle loss during first-line
EGFR-TKIs therapy in advanced lung adenocarcinoma patients.
BMC Cancer. 2025;25:393.
PubMed
Abstract available
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in
the setting of renal impairment: a retrospective study.
BMC Cancer. 2025;25:388.
PubMed
Abstract available
Correction: CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer
tumor models.
BMC Cancer. 2025;25:386.
PubMed
F-18 FDG PET-derived imaging biomarkers of airway inflammation and their clinical
associations in patients with non-small cell lung cancer.
BMC Cancer. 2025;25:379.
PubMed
Abstract available
Impact of single-port versus three-port video-assisted thoracic surgery lobectomy
on postoperative pain and quality of life in early-stage non-small cell lung
cancer patients: a meta-analysis.
BMC Cancer. 2025;25:400.
PubMed
Abstract available
Preoperative heart rate variability as a predictor of postoperative pneumonia and
lung function recovery in surgical lung cancer patients: a prospective observed
study.
BMC Cancer. 2025;25:404.
PubMed
Abstract available
Luteolin as an adjuvant effectively enhanced the efficacy of adoptive
tumor-specific CTLs therapy.
BMC Cancer. 2025;25:411.
PubMed
Abstract available
Top advances of the year: Small cell lung cancer.
Cancer. 2025;131:e35770.
PubMed
Abstract available
A single-cell map of patients with non-small cell lung cancer harboring
rare-driver mutations after anti-PD-1 treatment.
Cancer Lett. 2025;616:217595.
PubMed
Abstract available
Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung
Cancer by Activation of Akt and EGFR.
Cancer Res. 2025;85:1003.
PubMed
Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing
cancer-associated fibroblast activation.
Cancer Sci. 2025;116:792-807.
PubMed
Abstract available
Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC.
Cancer Sci. 2025;116:581-591.
PubMed
Abstract available
Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR
Amplification After First-Generation EGFR-TKI Resistance.
Cancer Sci. 2025;116:753-763.
PubMed
Abstract available
Germline alteration analysis reveals EPHB4R91H mutation as a key player in
multiple primary lung tumors.
Carcinogenesis. 2025;46:bgae074.
PubMed
Abstract available
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR
Mutated and Wild-Type Non-Small Cell Lung Cancer.
Clin Cancer Res. 2025 Mar 6. doi: 10.1158/1078-0432.CCR-24-3347.
PubMed
Abstract available
Genomic Profiling of Driver Gene Alterations in Patients With Non-Small Cell Lung
Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center
Experience of More Than 1200 Patients.
Clin Lung Cancer. 2025 Feb 11:S1525-7304(25)00026.
PubMed
Abstract available
Supraclavicular Lymph Node Metastases in Advanced Lung Cancer: Prevalence and
Analysis of Demographic, Clinical and Molecular Characteristics.
Clin Lung Cancer. 2025 Feb 8:S1525-7304(25)00033.
PubMed
Abstract available
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With
Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High
(>/=50%) Patients.
Clin Lung Cancer. 2025 Feb 4:S1525-7304(25)00025.
PubMed
Abstract available
Pulmonary Metastases From Early-stage Granulosa Cell Tumor 15 Years Later on
18F-NOTA-FAPI-04 and 18F-FDG PET/CT.
Clin Nucl Med. 2025 Mar 3. doi: 10.1097/RLU.0000000000005801.
PubMed
Abstract available
Histological proven AI performance in the UKLS CT lung cancer screening study:
Potential for workload reduction.
Eur J Cancer. 2025;220:115324.
PubMed
Abstract available
Action plan for an international imaging framework for implementation of global
low-dose CT screening for lung cancer.
Eur J Cancer. 2025;220:115323.
PubMed
Abstract available
Recurrent respiratory papillomatosis in adults with lower respiratory tract
involvement: a retrospective study of the OrphaLung and GETIF networks.
Eur Respir J. 2025;65:2400618.
PubMed
Abstract available
[Retracted] Feroniellin A?induced autophagy causes apoptosis in
multidrug?resistant human A549 lung cancer cells.
Int J Oncol. 2025;66:30.
PubMed
Abstract available
Targeting the secretory program of 3q-amplified lung cancers.
J Clin Invest. 2024;134:e181798.
PubMed
Abstract available
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
J Clin Oncol. 2025;43:1006-1038.
PubMed
Abstract available
The Effect of Multimodal Prehabilitation on Postoperative Outcomes in Lung Cancer
Surgery.
J Thorac Cardiovasc Surg. 2025 Mar 3:S0022-5223(25)00173.
PubMed
Abstract available
Improved Event-Free Survival After Complete or Major Pathologic Response in
Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy
Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data
Meta-Analysis.
J Thorac Oncol. 2025;20:285-295.
PubMed
Abstract available
Enlarging the Reach of Screening and Early Detection of Lung Cancer.
J Thorac Oncol. 2025;20:249-251.
PubMed
Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary
Metastases With Emphasis on Pathological and Molecular Considerations:
Recommendations From the International Association for the Study of Lung Cancer
Pathology Committee.
J Thorac Oncol. 2025;20:311-330.
PubMed
Abstract available
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With
Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3
PEARL Study.
J Thorac Oncol. 2025;20:366-382.
PubMed
Abstract available
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with
advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results
from a multicentre, single-arm study.
Lancet Oncol. 2025 Feb 25:S1470-2045(25)00012.
PubMed
Abstract available
Prospective cohort study of Suture-Line recurrence and clinical outcomes in stage
1A Non-Small cell lung cancer.
Lung Cancer. 2025;202:108465.
PubMed
Abstract available
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but
not agreement between assays in resectable non-small cell lung cancer.
Lung Cancer. 2025;202:108463.
PubMed
Abstract available
Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20
years of progress of novel therapies.
Lung Cancer. 2025;202:108453.
PubMed
Abstract available
Site-specific follow-up strategy for surgically resected patients with NSCLC
based on ten-year follow-up data.
Lung Cancer. 2025;201:108451.
PubMed
Abstract available
Exploration of clinical Biomarkers for guiding treatment selection between
chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin,
and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The
SPIRAL-STEP study.
Lung Cancer. 2025;201:108447.
PubMed
Abstract available
Immune landscape and novel therapeutic targets of epidermal growth factor
receptor and anaplastic lymphoma kinase wild type never-smoker lung
adenocarcinoma.
Lung Cancer. 2025;201:108448.
PubMed
Abstract available
EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC
in a real-world setting: A retrospective analysis of a US-based electronic health
records database.
Lung Cancer. 2025;201:108412.
PubMed
Abstract available
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+
NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
Lung Cancer. 2025;201:108424.
PubMed
Abstract available
Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological
features and molecular alterations in twenty-one cases.
Lung Cancer. 2025;201:108414.
PubMed
Abstract available
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding
Potent Anticancer Effects by Combination with Pembrolizumab.
Mol Cancer Ther. 2025;24:354-369.
PubMed
Abstract available
Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET
Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models.
Mol Cancer Ther. 2025;24:392-405.
PubMed
Abstract available
Potential Crosstalk Between ANXA1+ Epithelial Cells and FABP4+ TAM Cells of
Ferroptosis-Related Molecular Clusters Promotes an Immunosuppressive
Microenvironment in Non-Small Cell Lung Cancer.
Mol Carcinog. 2025 Mar 4. doi: 10.1002/mc.23899.
PubMed
Abstract available
Pan?cancer analysis of oncogene SFXN1 to identify its prognostic and
immunological roles in lung adenocarcinoma.
Oncol Rep. 2025;53:50.
PubMed
Abstract available
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American
patients (CLICaP).
Oncologist. 2025;30:oyae347.
PubMed
Abstract available
Patients' psychosocial attributes and aggressiveness of cancer treatments near
the end of life.
Oncologist. 2025;30:oyae317.
PubMed
Abstract available
Lung cancer screening with volume computed tomography is cost-effective in
Greece.
PLoS One. 2025;20:e0316351.
PubMed
Abstract available
Self-blaming as a barrier to lung cancer screening and smoking cessation programs
in Italy. A qualitative study.
PLoS One. 2025;20:e0318732.
PubMed
Abstract available
Retraction: Integrative analyses identify osteopontin, LAMB3 and ITGB1 as
critical pro-metastatic genes for lung cancer.
PLoS One. 2025;20:e0320171.
PubMed
EGFR-induced lncRNA TRIDENT promotes drug resistance in non-small cell lung
cancer via phospho-TRIM28-mediated DNA damage repair.
Proc Natl Acad Sci U S A. 2025;122:e2415389122.
PubMed
Abstract available
Thank you for your interest in scientific medicine.